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Polyglutamine diseases are caused by an expanded glutamine domain thought to confer a 
toxic activity onto the respective disease proteins. In this issue, Lam et al. (2006) propose 
that toxicity of the polyglutamine protein Ataxin-1 may not be due to abberant protein 
interactions mediated by the polyglutamine expansion. Instead, they suggest that toxicity 
is solely due to interactions of Ataxin-1 with its normal binding partners.A cohort of nine neurodegenerative 
disorders, including Huntington’s 
disease and the spinocerebellar 
ataxias (SCAs), are caused by poly-
glutamine (polyQ) expansions in the 
respective host proteins (Taylor et 
al., 2002). The polyQ expansion is 
thought to confer a dominant gain 
of function on the disease protein, 
leading to cellular dysfunction and 
degeneration. Despite the recognized 
toxic nature of long polyQ tracts, the 
polyQ diseases are clinically distinct, 
affecting different brain regions and/
or neuronal types. These and other 
data indicate that host protein con-
text is a crucial aspect of disease, 
presumably modulating toxicity con-
ferred by the polyQ expansion. In 
this issue, Lam et al. (2006) make 
the proposal that neuropathology in 
SCA1 is due solely to interactions of 
the polyQ disease protein Ataxin-1 
within its normal protein interaction 
network. If this view is applied to 
other polyQ disorders, the implica-
tion is that each disease has individ-
ual molecular pathologies depend-
ent upon each disease protein’s 
interaction network, sharing only the 
common initiating event of a polyQ 
expansion.
Toxicity in polyQ diseases is 
thought to have multiple layers, with 
study of these layers leading toward 
a complete understanding of dis-
ease pathogenesis, from early trig-
gers to late events. With the causal mutation defined as a polyQ domain 
expansion, initial expectations were 
that this tract would not only be nec-
essary, but possibly sufficient, to 
trigger neurotoxicity. However, with 
increased study of the disease pro-
teins mutated in each specific situ-
ation, host protein context emerged 
as a key feature; a striking example is 
Figure 1. Models for PolyQ Pathogenesis
Two models for polyQ disease pathogenesis 
are shown. 
(Top) In this model, the individual polyQ pro-
teins (such as those that cause Huntington’s 
disease or the spinocerebellar ataxias) trigger 
common pathogenic events that lead to neu-
ronal degeneration. 
(Bottom) In contrast, in the model suggested 
by Lam et al. (2006), pathogenic proteins 
of the different diseases, despite sharing a 
common mutational event (polyQ expansion), 
act within their individual native network of 
protein interactions to alter functionality in 
ways that lead to neurodegeneration. In this 
case, the pathogenic events would be solely 
dependent upon host protein context, and, 
unless different host proteins share functions 
or interacting partners (see Lim et al., 2006), 
these events would be distinct among differ-
ent polyQ diseases.Cell 127, Decemthe ligand-dependent toxicity of the 
androgen receptor mutated in the 
polyQ disease spinobulbar muscular 
atrophy (Takeyama et al., 2002).
For Ataxin-1, previous efforts 
defined a complex network of inter-
acting proteins proposed to modu-
late Ataxin-1 function under both 
normal and disease conditions (Lim 
et al., 2006). Now Lam et al. (2006) 
have defined in greater detail inter-
actions with another member of 
the Ataxin-1 protein network, Capi-
cua. The new findings indicate that 
altered aspects, but solely of the 
normal activities of the Ataxin-1 
protein, may underlie pathogenesis 
in SCA1 disease (Figure 1).
A fundamental question of these 
diseases is the contribution of aber-
rant native protein interactions rela-
tive to new interactions imparted 
by the polyQ expansion. To provide 
potential clues, Zoghbi, Orr, and col-
leagues have been characterizing 
the protein network in which Ataxin-
1 participates and then asking the 
extent to which each of these inter-
actions is altered by a polyQ expan-
sion. Intriguingly, they establish 
that Ataxin-1 can be purified from 
cerebellum in huge protein com-
plexes (> 1 MDa) that also contain 
the previously identified direct inter-
acting protein Capicua (Lam et al., 
2006). Analysis revealed that mutant 
Ataxin-1 remains within these com-
plexes. In addition, an expanded ber 29, 2006 ©2006 Elsevier Inc. 1299
polyQ protein with an S776A point 
mutation, which has attenuated tox-
icity, is not incorporated into these 
complexes, suggesting that the 
complexes contribute to toxicity. 
This raises the possibility that toxic-
ity dictated by Ataxin-1 is dependent 
on its native protein interaction net-
work and not on new protein interac-
tions conferred by the polyQ expan-
sion. Moreover, expanded Ataxin-1 
decreases Capicua-dependent tran-
scriptional repression, consistent 
with the notion that compromising 
the activity of the complexes con-
tributes to disease.
Hints that the normal function of 
Ataxin-1 may contribute to toxicity 
previously emerged from studies 
in the fruit fly Drosophila, a popu-
lar system for molecular genetic 
approaches to understanding human 
disease, especially those involv-
ing polyQ expansion (Marsh and 
Thompson, 2006; Bilen and Bonini, 
2005). Surprisingly, the fly revealed 
that the effects of polyQ-expanded 
Ataxin-1 are remarkably similar to 
those of the normal, unexpanded 
Ataxin-1 protein (Fernandez-Funez 
et al., 2000). This indicated that sim-
ply too much of the normal protein, 
rather than the polyQ expansion, is 
sufficient for the neurotoxic pheno-
type. Indeed, the primary effect of 
an expanded polyQ repeat within 
Ataxin-1 may be to augment native 
interactions of the disease protein, 
due, at least in part, to simply caus-
ing an abnormally high level of the 
protein to accumulate. This prop-
erty, that too much of the normal 
protein may be toxic, is a feature of 
other disease proteins, such as α-
synuclein implicated in Parkinson’s 
disease (Eriksen et al., 2005).
These studies raise the idea that 
host protein function and its normal 
interactions are the key to patho-
genesis of polyQ disease proteins. 
This contrasts with the view that 
disease pathogenesis is caused by 
the polyQ alone, or a combination 
of events, with some triggered by 1300 Cell 127, December 29, 2006 ©2006the disease protein acting within its 
normal framework while others are 
conferred by the polyQ expansion 
and are shared among the different 
diseases. Thus, focusing on nor-
mal protein activity may yield key 
insights into disease pathogenesis.
However, although pathogenic 
Ataxin-1 appears similar in prop-
erties to the normal protein, there 
remain some potentially intriguing 
differences. For example, the sedi-
mentation of Ataxin-1 complexes 
containing the pathogenic protein 
is not identical to that of complexes 
containing the normal protein, indi-
cating that mutant Ataxin-1 may 
be part of different complexes. 
Moreover, mice with high levels of 
the normal protein show some fea-
tures of mice expressing the patho-
genic protein but may not develop 
full disease; meanwhile, aspects 
of fly phenotypes appear selective 
for a pathogenic polyQ. Key ques-
tions to further test the current data 
include defining the role of Capicua 
in Ataxin-1 pathogenesis and deter-
mining whether loss of Capicua 
alone results in features of SCA1 
disease. What genes are normally 
regulated by the Ataxin-1/Capicua 
complex, and what is their role in 
disease? Also, beyond Ataxin-1, is 
this principle—that too much of nor-
mal is mutant—applicable to other 
polyQ disease proteins?
In the bigger picture, how do 
these findings fit into current ideas 
of protein misfolding and toxicity? 
Oligomeric forms, but not mono-
meric forms or large accumulations 
of pathogenic proteins, are currently 
thought to be the toxic species in 
various neurodegenerative dis-
eases, including polyQ expansion 
disorders (Kayed et al., 2003). Yet, 
presumably, native interactions are 
dependent on native protein folding 
and would be disrupted by misfold-
ing associated with oligomers. Such 
toxic forms may also be a small sub-
set of the major interactions of a dis-
ease protein, or sufficiently unstable  Elsevier Inc.or transient, such that new interac-
tions in disease pathogenesis may 
be cryptic to define. Moreover, other 
pathways, such as the microRNA 
pathway (Bilen et al., 2006), dramat-
ically modulate polyQ toxicity, and 
these pathways may play specific 
as well as common roles in disease. 
Chaperones also broadly affect tox-
icity, and pathways of cell loss may 
be shared. 
The findings by Lam et al. (2006) 
provide an important foundation to 
examine the fundamental basis of 
polyQ disease. If disease features 
depend solely on native protein 
interactions, then the polyQ dis-
eases, despite sharing a common 
mutational basis, will have dis-
tinctive mechanisms of neuronal 
degeneration dependent on the 
native complexes of each individual 
disease protein.
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